Precision BioSciences, Inc. (DTIL): Price and Financial Metrics
DTIL Price/Volume Stats
| Current price | $10.72 | 52-week high | $28.44 |
| Prev. close | $11.51 | 52-week low | $8.25 |
| Day low | $10.70 | Volume | 71,800 |
| Day high | $11.66 | Avg. volume | 129,838 |
| 50-day MA | $12.95 | Dividend yield | N/A |
| 200-day MA | $12.85 | Market Cap | 74.14M |
DTIL Stock Price Chart Interactive Chart >
Precision BioSciences, Inc. (DTIL) Company Bio
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.
Latest DTIL News From Around the Web
Below are the latest news stories about PRECISION BIOSCIENCES INC that investors may wish to consider to help them evaluate DTIL as an investment opportunity.
Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECUREDURHAM, N.C., December 13, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that its partner iECURE has received approval from the Australian Therapeutic Goods Administration for the initiation of a first-in-human Phase 1/2 trial evaluating ECUR-506, incorporating an ARCUS nuc |
Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial DiseasesDURHAM, N.C., December 04, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced publication in the journal Nature Metabolism of a peer reviewed manuscript titled "Efficient elimination of MELAS-associated m.3243G mutant mitochondrial DNA by an engineered mitoARCUS nuclease." This |
Precision BioSciences to Present at Hep-DART 2023DURHAM, N.C., November 30, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the company will present at Hep-DART 2023 in an industry session and host a poster presentation on December 5, 2023, in Los Cabos, Mexico. |
Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)DURHAM, N.C., November 28, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on November 21, 2023, the Compensation Committee of Precision’s Board of Directors approved the grant of an inducement award to a new employee under the Precision BioSciences, Inc. 2021 Employmen |
Sidoti Events, LLC’s Virtual November Micro-Cap ConferenceNEW YORK, NY / ACCESSWIRE / November 14, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day November Micro-Cap Conference taking place Wednesday and Thursday, November ... |
DTIL Price Returns
| 1-mo | -12.35% |
| 3-mo | -6.21% |
| 6-mo | 20.35% |
| 1-year | -60.73% |
| 3-year | -95.80% |
| 5-year | -97.07% |
| YTD | -2.10% |
| 2023 | -69.33% |
| 2022 | -83.92% |
| 2021 | -11.27% |
| 2020 | -39.96% |
| 2019 | N/A |
Loading social stream, please wait...